

ISMP MEDICATION SAFETY SELF ASSESSMENT®

FOR HIGH-ALERT MEDICATIONS - ASSESSMENT OF THE SAFETY OF SYSTEMS AND PRACTICES ASSOCIATED WITH SIX CATEGORIES OF HIGH-ALERT MEDICATIONS




A. SONNLEITNER-HEGLMEIER, M. JESKE, C. PETTER, S. GRIMM, S. KERNDLER, U. HORVATH, J. PRENNER
INNSBRUCK, UNIVERSITY HOSPITAL, PHARMACY DEPARTEMENT, AUSTRIA

PSQ10322

abstract:

Due to limited personal resources clinical pharmacy services at the University Hospital of Innsbruck, Austria, are currently quite rare. To raise the awareness towards clinical pharmacy and highlight the impact of a collaboration with clinical pharmacists, we discussed the ISMP Medication Safety Self Assessment® in several meetings with multidisciplinary teams.



ISMP Medication Safety Self Assessment®

In 2017, the Institute for Safe Medication Practices, USA published an assessment, for high-alert medication, to highlight difficulties in medication practices and systems. This assessment is meant to be discussed in multidisciplinary teams and gives the opportunity to evaluate risk in several pharmaceutical steps, given in a hospital setting

Chapters discussed:

Opioids, Insulin, Anticoagulants, Methotrexate for non-oncological indications, Muscle Relaxant, Chemotherapeutics

Contact:

Mag. pharm. Angelina Sonnleitner-Heglmeier, MSc
Clinical Pharmacy/ Medication Information Service
Klinische Pharmazie/Arzneimittelinformationsdienst
Apotheke des A.ö. Landeskrankenhauses – Univ.-Kliniken Innsbruck
Tirol Kliniken GmbH – www.tirol-kliniken.at
angelina.sonnleitner-heglmeier@tirol-kliniken.at

Literature:

ISMP Medication Safety Self Assessment® for High-Alert Medications / Verf. ISMP Institute for Safe Medication Practices. - Horsham : [s.n.], 2017.

